Equities

United Laboratories International Holdings Ltd

United Laboratories International Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)10.24
  • Today's Change0.22 / 2.20%
  • Shares traded3.31m
  • 1 Year change+27.05%
  • Beta0.5934
Data delayed at least 15 minutes, as of Nov 26 2024 07:45 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments4,2624,7433,331
Total Receivables, Net6,3144,9123,800
Total Inventory2,2382,1642,004
Prepaid expenses------
Other current assets, total972697851
Total current assets13,78712,5159,986
Property, plant & equipment, net7,0046,2666,131
Goodwill, net3.033.033.03
Intangibles, net134100120
Long term investments7.807.660.50
Note receivable - long term----0
Other long term assets------
Total assets21,01718,98016,331
LIABILITIES
Accounts payable4,2203,5583,211
Accrued expenses782797673
Notes payable/short-term debt000
Current portion long-term debt/capital leases2001,3631,614
Other current liabilities, total1,4241,3141,038
Total current liabilities6,6277,0336,535
Total long term debt1,3031,100228
Total debt1,5042,4631,842
Deferred income tax288194172
Minority interest131.35(0.58)
Other liabilities, total514355
Total liabilities8,2828,3726,991
SHAREHOLDERS EQUITY
Common stock171717
Additional paid-in capital3,7223,7223,782
Retained earnings (accumulated deficit)8,9866,8605,551
Treasury stock - common00(18)
Unrealized gain (loss)------
Other equity, total9.539.117.68
Total equity12,73510,6089,340
Total liabilities & shareholders' equity21,01718,98016,331
Total common shares outstanding1,8171,8171,829
Treasury shares - common primary issue004.72
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.